Efficacy and safety analysis of pabolizumab plus low-dose apatinib combined chemotherapy in elderly patients with esophageal cancer
10.3969/j.issn.1006-5725.2024.24.016
- VernacularTitle:帕博利珠单抗加小剂量阿帕替尼联合治疗老年食管癌的有效性及安全性
- Author:
Tingting ZHANG
1
;
Ke LIU
;
Dan CHEN
;
Bingwen YAN
;
Peijuan ZHAO
;
Ning WANG
Author Information
1. 胜利油田中心医院肿瘤科(山东 东营 257000)
- Publication Type:Journal Article
- Keywords:
pabolizumab;
apatinib;
chemotherapy;
esophageal cancer;
old age;
security;
effectiveness
- From:
The Journal of Practical Medicine
2024;40(24):3534-3538
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of pabolizumab plus low-dose apatinib combined chemotherapy in elderly patients with esophageal cancer.Methods A total of 188 elderly patients with esophageal cancer admitted to Shengli Oilfield Central Hospital from May 2020 to July 2022 were selected and divided into study group(n=94)and control group(n=94)by random number table method.The control group received pabolizumab combined with FP chemotherapy regimen,and the study group received low-dose Apatinib combined with Pabolizumab and FP chemotherapy regimen.Clinical efficacy,tumor markers,phosphatidylinositol 3 kinase(PI3K)/threonine protein kinase(Akt)signaling protein pathway,immune function,adverse reactions and survival were compared between the two groups.Results The objective remission rate of the study group was higher than control group(P＜0.05).After treatment,squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),PI3K,Akt and CD8+were all decreased in the two groups(P＜0.05),and those in study group were lower(P＜0.05).After treatment,CD3+and CD4+were increased in both groups(P＜0.05),and higher in study group(P＜0.05).There was no difference in the total incidence of adverse reactions between the two groups(P＞0.05).The survival rate of the study group was higher than control group(P＜0.05).Conclusion Pabolizumab plus low-dose apatinib combined with chemotherapy is effective in the treatment of elderly esophageal cancer,which may inhibit tumor progression by reducing the activity of PI3K/Akt signaling protein pathway and improve the short-term survival rate.
